BriaCell’s Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout
BriaCell Therapeutics Corp. - Common Shares (BCTX)
Company Research
Source: GlobeNewswire
Over 230 patients screened and over 160 patients enrolled in BriaCell’s pivotal Phase 3 study in metastatic breast cancer (MBC)Enrollment exceeding expectations with strong clinical site and patient interestTopline interim data readout expected in 1H2026 Phase 3 combination regimen continues under FDA Fast Track designation PHILADELPHIA and VANCOUVER, British Columbia, Dec. 09, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to announce its Phase 3 clinical study has screened over 230 and enrolled over 160 patients. BriaCell anticipates reporting topline data as early as 1H2026. Interim data will be analyzed once 144 patient events (deaths) occur. Positive results from this pivotal study could support full approval and marketing authorization of Bria-IMT™ in patients with metastatic breast cancer. BriaCe
Show less
Read more
Impact Snapshot
Event Time:
BCTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCTX alerts
High impacting BriaCell Therapeutics Corp. - Common Shares news events
Weekly update
A roundup of the hottest topics
BCTX
News
- BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025GlobeNewswire
- BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025GlobeNewswire
- BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025GlobeNewswire
- BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer TherapeuticsGlobeNewswire
- BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025GlobeNewswire
BCTX
Sec Filings
- 12/11/25 - Form 10-Q
- 12/1/25 - Form 8-K
- 11/7/25 - Form SCHEDULE
- BCTX's page on the SEC website